4-羟基-5,7-二甲氧基-3-喹啉甲腈 | 331662-65-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-羟基-5,7-二甲氧基-3-喹啉甲腈
• 中文别名: 4-羟基-5,7-二甲氧基喹啉-3-甲腈
• 英文名称: 5,7-dimethoxy-4-hydroxy-3-quinolinecarbonitrile
• 英文别名: 5,7-dimethoxy-4-oxo-1H-quinoline-3-carbonitrile
• CAS: 331662-65-8
• 化学式: C₁₂H₁₀N₂O₃
• mdl: MFCD09951496
• 分子量: 230.223
• InChiKey: VULJFGGTQMATOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  71.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  4-羟基-5,7-二甲氧基-3-喹啉甲腈 在 三氯氧磷 作用下， 生成 4-氯-5,7-二甲氧基喹啉-3-甲腈
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of 3-Cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) Inhibitors

  摘要：

  A series of 3-cyano-4-(phenoxyanilino)cyanoquinolines has been prepared as MEK (MAP kinase kinase) inhibitors. The best activity is seen with alkoxy groups at both the 6- and 7-positions. The lead compounds show low nanomolar IC50's against MAP kinase kinase, and have potent inhibitory activity in tumor cells. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00580-1
• 作为产物：
  描述：

  2-氨基-4,6-二甲氧基苯甲酸甲酯 以 四氢呋喃 为溶剂， 生成 4-羟基-5,7-二甲氧基-3-喹啉甲腈
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of 3-Cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) Inhibitors

  摘要：

  A series of 3-cyano-4-(phenoxyanilino)cyanoquinolines has been prepared as MEK (MAP kinase kinase) inhibitors. The best activity is seen with alkoxy groups at both the 6- and 7-positions. The lead compounds show low nanomolar IC50's against MAP kinase kinase, and have potent inhibitory activity in tumor cells. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00580-1
• 作为试剂：
  描述：

  3-cyano-7-fluoro-4-hydroxy-5-[(1-methylpiperidin-4-yl)oxy]quinoline 、 甲醇 、 potassium tert-butylate 、 盐酸 在 4-羟基-5,7-二甲氧基-3-喹啉甲腈 、 水 、 水合甲醇 、 甲醇 、 三乙胺 作用下， 以 二甲基亚砜 、 水 为溶剂， 反应 16.0h， 以This gave the title compound as an white solid (460 mg, 73%)的产率得到3-cyano-4-hydroxy-7-methoxy-5-[(1-methylpiperidin-4-yl)oxy]quinoline
  参考文献：
  名称：

  Substituted 3-cyanoquinolines as MEK inhibitors

  摘要：

  本发明涉及公式（I）的喹啉衍生物，其中Z1，m，R1，n，R3，Z2和R14中的每个具有前述描述中定义的任何含义；它们的制备过程，包含它们的制药组合物以及它们在制造用于抑制侵袭性或增殖性药物的制剂中的应用，用于治疗和/或治疗实体肿瘤疾病。

  公开号：

  US20070213367A1

文献信息

• [EN] SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS<br/>[FR] 3-CYANOQUINOLEINES SUBSTITUEES UTILISEES COMME INHIBITEURS DE MEK
  申请人：ASTRAZENECA AB

  公开号：WO2004005284A1

  公开（公告）日：2004-01-15

  The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹啉衍生物，其中Z1、m、R1、n、R3、Z2和R14中的每一个具有在描述中先前定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗侵袭或抗增殖剂的药物的用途中，用于包含和/或治疗实体肿瘤疾病。
• Substituted 3-cyanoquinolines as mek inhibitors
  申请人：Hennequin Francois Andre Laurent

  公开号：US20060089382A1

  公开（公告）日：2006-04-27

  The invention concerns quinoline derivatives of Formula (I) wherein each of Z 1 , m, R 1 , n, R 3 , Z 2 and R 14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

  本发明涉及公式（I）的喹啉衍生物，其中Z1，m，R1，n，R3，Z2和R14中的每一个都具有在描述中定义的任何含义; 用于其制备的过程，包含它们的制药组合物以及它们用于制造用作抗侵袭或抗增殖剂的药物，用于包含和/或治疗实体肿瘤疾病。
• Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3-quinolinecarbonitriles
  作者：Diane H. Boschelli、Yanong D. Wang、Fei Ye、Biqi Wu、Nan Zhang、Minu Dutia、Dennis W. Powell、Allan Wissner、Kim Arndt、Jennifer M. Weber、Frank Boschelli

  DOI：10.1021/jm000420z

  日期：2001.3.1

  Screening of a directed compound library in a yeast-based assay identified 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile (2a) as a Src inhibitor. An enzymatic assay established that 2a was an ATP-competitive inhibitor of the kinase activity of Src. We present here SAR data for 2a which shows that the aniline group at C-4, the carbonitrile group at C-3, and the alkoxy groups at C-6 and C-7 of the quinoline are crucial for optimal activity. Increasing the size of the C-2 substituent of the aniline at C-4 of 2a from chloro to bromo to iodo resulted in a corresponding increase in Src inhibition. Furthermore, replacement of the 7-methoxy group of 2a with various 3-heteroalkylaminopropoxy groups provided increased inhibition of both Src enzymatic and cellular activity. Compound 25, which contains a 3-morpholinopropoxy group, had an IC50 of 3.8 nM in the Src enzymatic assay and an IC50 of 940 nM for the inhibition of Src-dependent cell proliferation.
• SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS
  申请人：Astrazeneca AB

  公开号：EP1521751A1

  公开（公告）日：2005-04-13
• US7173135B2
  申请人：——

  公开号：US7173135B2

  公开（公告）日：2007-02-06